Uroplasty (NASDAQ: UPI) and Stryker (NYSE:SYK) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, risk, valuation and dividends.
Stryker pays an annual dividend of $1.88 per share and has a dividend yield of 1.2%. Uroplasty does not pay a dividend. Stryker pays out 70.1% of its earnings in the form of a dividend. Uroplasty has raised its dividend for 7 consecutive years.
Risk and Volatility
Uroplasty has a beta of -1.26, indicating that its stock price is 226% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.
This table compares Uroplasty and Stryker’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
This is a summary of current recommendations and price targets for Uroplasty and Stryker, as provided by MarketBeat.com.
||Strong Buy Ratings
Stryker has a consensus price target of $162.32, indicating a potential upside of 0.38%. Given Stryker’s higher possible upside, analysts plainly believe Stryker is more favorable than Uroplasty.
Earnings and Valuation
This table compares Uroplasty and Stryker’s top-line revenue, earnings per share and valuation.
||Earnings Per Share
Stryker has higher revenue and earnings than Uroplasty. Uroplasty is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
74.5% of Stryker shares are held by institutional investors. 7.4% of Stryker shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Stryker beats Uroplasty on 12 of the 14 factors compared between the two stocks.
Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company’s products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products. The MedSurg segment includes surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment, intensive care disposable products; reprocessed and remanufactured medical devices, and other related products. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. The Company’s products include implants, which are used in joint replacement and trauma surgeries, and other products that are used in a range of medical specialties.
Receive News & Ratings for Uroplasty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty and related companies with MarketBeat.com's FREE daily email newsletter.